

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7606503

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SCHRODINGER, LLC	09/16/2022
RECEIVING PARTY DATA	
Name:	ONO PHARMACEUTICAL CO., LTD.
Street Address:	1-5, DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA-SHI
City:	OSAKA
State/Country:	JAPAN
Postal Code:	541-8526
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17971844
CORRESPONDENCE DATA	
Fax Number:	(202)293-7860
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2022937060
Email:	aquiroa@sughrue.com, sughrue@sughrue.com
Correspondent Name:	SUGHRUE MION, PLLC
Address Line 1:	2000 PENNSYLVANIA AVENUE NW
Address Line 4:	WASHINGTON, D.C. 20006
ATTORNEY DOCKET NUMBER:	Q278477
NAME OF SUBMITTER:	ARI QUIROA
SIGNATURE:	/ARI QUIROA/
DATE SIGNED:	10/24/2022
Total Attachments: 4	
source=Q278477ExecutedAssignmentasfiledfromSchrodingerLLCtoONOPHARMACEUTICAL#page1.tif	
source=Q278477ExecutedAssignmentasfiledfromSchrodingerLLCtoONOPHARMACEUTICAL#page2.tif	
source=Q278477ExecutedAssignmentasfiledfromSchrodingerLLCtoONOPHARMACEUTICAL#page3.tif	
source=Q278477ExecutedAssignmentasfiledfromSchrodingerLLCtoONOPHARMACEUTICAL#page4.tif	

ASSIGNMENT

WHEREAS, Schrödinger, LLC, a corporation organized under and pursuant to the laws of Delaware of the United States of America located at 1540 Broadway, 24th Floor, New York, New York 10036, United States of America (hereinafter referred to as "**ASSIGNOR**"), is the owner of right, title, and interest, throughout the world, in and to: (a) the patent applications listed in the attached Schedule A (Scheduled Applications) and the resulting patents, including the right to claim priority from the Scheduled Application (including the national stage entry applications) under international conventions and treaties, (b) any patent applications claiming priority from the Scheduled Application (including the national stage entry applications) under international conventions, treaties, or otherwise, and the patents resulting from the patent applications, and any direct or indirect divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the Scheduled Applications, and the resulting patents; and (c) any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents, including, without limitation, supplementary protection certificates) of the patents described in (a) and (b) above, by way of an assignment executed by inventors of above, as shown in the attached executed Assignment;

WHEREAS, Ono Pharmaceutical Co., Ltd., a corporation organized under and pursuant to the laws of Japan located at 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526 Japan (hereinafter referred to as "**ASSIGNEE**") desires to acquire the entire right, title, and interest, owned by Schrödinger, Inc., throughout the world, in and to the intellectual property rights to (a) - (c) above.

NOW, THEREFORE, for good and valuable consideration, the receipt whereof is hereby acknowledged, ASSIGNOR hereby assigns, sells, and transfers to ASSIGNEE, its assigns and legal representatives, its entire right, title, and interest, throughout the world, in and to: (a) the intellectual property rights described in Scheduled Applications and the resulting patents, including the right to claim priority from the Scheduled Application (including the national stage entry applications) under international conventions and treaties; (b) any patent applications claiming priority from the Scheduled Applications (including the national stage entry applications) under international conventions, treaties, or otherwise, and the patents resulting from the patent applications, and any direct or indirect divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the Scheduled Applications, and the resulting patents; and (c) any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents, including, without limitation, supplementary protection certificates) of the patents described in (a) and (b) above, as a consequence of which ASSIGNEE, its assigns and legal representatives have had, held, exercised and enjoyed the entire right, title, and interest in and to the (a), (b), and (c) above, with all the rights, powers, privileges, and advantages arising from or appertaining thereto, for and during the term or terms of said patent applications or patents, for use and benefit of ASSIGNEE, its assigns and legal representatives, in as ample and beneficial a manner to all intents and purposes as ASSIGNOR might or could have held and enjoyed the

same, if the assignment had not been made.

And, ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority to issue any patents resulting from the patent applications to ASSIGNEE.

This Agreement may be executed in separate counterparts, each of which shall be identical and may be introduced in evidence or used for any other purpose without any other counterpart, but all of which shall together constitute one and the same agreement. Any such counterparts even if it's executed and/or transmitted electronically via the trusted electronic signature vendor, including scanned signed documents or digital signatures, shall bind the Parties to the same extent as documents with original signatures.

Schrödinger, LLC

By:

Dated: 9/16/22

s/ [Signature]
Name: [Signature]
Title: [Signature]

ACCEPTANCE BY ASSIGNEE

I hereby accept this assignment on behalf of ASSIGNEE, I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that I am an officer of ASSIGNEE, that I have signed this document on behalf of ASSIGNEE, with the full authority of its board of directors, and that all the foregoing is true and correct.

Ono Pharmaceutical Co., Ltd.

By:

Dated: _____

s/ _____
Name: Kazuyuki OHMOTO
Title: Senior Director, IP Strategy

which ASSIGNEE, its assigns and legal representatives have had, held, exercised and enjoyed the entire right, title, and interest in and to the (a), (b), and (c) above, with all the rights, powers, privileges, and advantages arising from or appertaining thereto, for and during the term or terms of said patent applications or patents, for use and benefit of ASSIGNEE, its assigns and legal representatives, in as ample and beneficial a manner to all intents and purposes as ASSIGNOR might or could have held and enjoyed the same, if the assignment had not been made.

And, ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority to issue any patents resulting from the patent applications to ASSIGNEE.

This Agreement may be executed in separate counterparts, each of which shall be identical and may be introduced in evidence or used for any other purpose without any other counterpart, but all of which shall together constitute one and the same agreement. Any such counterparts even if it's executed and/or transmitted electronically via the trusted electronic signature vendor, including scanned signed documents or digital signatures, shall bind the Parties to the same extent as documents with original signatures.

Schrödinger, LLC

By:

Dated: _____

s/ _____

Name: _____

Title: _____

ACCEPTANCE BY ASSIGNEE

I hereby accept this assignment on behalf of ASSIGNEE, I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that I am an officer of ASSIGNEE, that I have signed this document on behalf of ASSIGNEE, with the full authority of its board of directors, and that all the foregoing is true and correct.

Ono Pharmaceutical Co., Ltd.

By:

Dated: September 22, 2022

s/  _____

Name: Kazuyuki OHMOTO

Title: Senior Director, IP Strategy

SCHEDULE A

Country	Application No.	Filing Date	Title
PCT	PCT/CN2020/088925	May 7, 2020	COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
PCT	PCT/CN2021/091843	May 6, 2021	COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF (also "3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF" as appeared in WO2021/223699)
TW	110116409	May 6, 2021	COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF